Immunic, inc. announces emphasis interim analysis of 10 mg cohort confirms imu-838's dose response in relapsing-remitting multiple sclerosis and supports phase 3 dose selection

New york, april 15, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced interim data from cohort 2 of its phase 2 emphasis trial of imu-838 in relapsing-remitting multiple sclerosis (rrms). immunic has concluded from this data, along with previously published data from cohort 1, that 30 mg once daily imu-838 is the most appropriate dose for future phase 3 trials in patients with rrms.
IMUX Ratings Summary
IMUX Quant Ranking